Sign up to save your podcasts
Or
Share Janet Brown on the phase 2/3 STAR trial
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Janet Brown on the phase 2/3 STAR trial
Prof Janet Brown (University of Sheffield, Sheffield, UK) discusses the phase 2/3 STAR trial on treatment cessation versus continuation with tyrosine kinase inhibitors in advanced renal cell carcinoma.
Read the full article:
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR)
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
View all episodes
By The Lancet Group
5
11 ratings
Prof Janet Brown (University of Sheffield, Sheffield, UK) discusses the phase 2/3 STAR trial on treatment cessation versus continuation with tyrosine kinase inhibitors in advanced renal cell carcinoma.
Read the full article:
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR)
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
More shows like The Lancet Oncology in conversation with
View all
Nature Podcast
757 Listeners
Science Magazine Podcast
808 Listeners
JAMA Editors' Summary
127 Listeners
TED Talks Daily
11,282 Listeners
NEJM Interviews
125 Listeners
6 Minute English
1,782 Listeners
NEJM This Week
315 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Practical Neurology Podcast
35 Listeners
JAMA Clinical Reviews
476 Listeners
ASCO Daily News
55 Listeners
ASCO Guidelines
44 Listeners
The Readout Loud
318 Listeners
The Uromigos
57 Listeners
The Lancet Voice
23 Listeners
The Lancet Child & Adolescent Health in conversation with
0 Listeners
The Lancet Digital Health in conversation with
0 Listeners
The Lancet Global Health in conversation with
2 Listeners
The Lancet Psychiatry in conversation with
1 Listeners
The Lancet Respiratory Medicine in conversation with
1 Listeners
The Lancet in conversation with
0 Listeners
The Lancet Haematology in conversation with
0 Listeners
The Lancet Gastroenterology & Hepatology in conversation with
0 Listeners
The Lancet Diabetes & Endocrinology in conversation with
1 Listeners
The Lancet Infectious Diseases in conversation with
0 Listeners
The Lancet Healthy Longevity in conversation with
0 Listeners
The Lancet Public Health in conversation with
1 Listeners
The Lancet Microbe in conversation with
0 Listeners
In conversation with...
0 Listeners
eBioMedicine in conversation with
0 Listeners
eClinicalMedicine in conversation with
0 Listeners
The Lancet Rheumatology in conversation with
0 Listeners
Two Onc Docs
166 Listeners
The Lancet Regional Health in conversation with
0 Listeners